Oscar Health (OSCR) has revenue growth goals, but with limited short-term visibility, and margin and earnings estimates are expected to be below targets, UBS said in a note Monday.
The company is executing growth initiatives cautiously, projecting a revenue of $11.1 billion in 2025, and a more conservative stance for 2026 and 2027 due to the expiration of enhanced subsidies, the investment firm said.
Oscar Health projects a decline in membership, but aims to offset that through 8% growth in existing markets and 10% expansion into new markets by 2026, UBS noted.
The company has successfully reduced general and administrative costs per member to $100 from $170, signaling improved cost control measures, according to UBS.
UBS set a neutral rating and $23 price target for Oscar Health.
Price: 18.43, Change: -1.71, Percent Change: -8.49
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。